Compounds > aplysin
Page last updated: 2024-11-12

aplysin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aplysin: Antineoplastic Agents, Alkylating, derived from Laurencia tristicha; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11066347
CHEMBL ID463532
SCHEMBL ID10428585
MeSH IDM000599148

Synonyms (17)

Synonym
6790-63-2
nsc-305227
aplysin
inchi=1/c15h19bro/c1-9-7-13-11(8-12(9)16)14(3)6-5-10(2)15(14,4)17-13/h7-8,10h,5-6h2,1-4h3/t10-,14-,15-/m0/s
CHEMBL463532
C17132
nsc 305227
j22ivp9vtm ,
unii-j22ivp9vtm
1h-cyclopenta(b)benzofuran, 7-bromo-2,3,3a,8b-tetrahydro-3,3a,6,8b-tetramethyl-, (3s-(3alpha,3abeta,8bbeta))-
SCHEMBL10428585
1h-cyclopenta(b)benzofuran, 7-bromo-2,3,3a,8b-tetrahydro-3,3a,6,8b-tetramethyl-, (3s,3as,8bs)-
1h-cyclopenta(b)benzofuran, 7-bromo-2,3,3a,8b-tetrahydro-3,3a,6,8b-tetramethyl-, (3s-(3.alpha.,3a.beta.,8b.beta.))-
(-)-aplysin
aplysin, (-)-
Q27281046
(3s,3as,8bs)-7-bromo-3,3a,6,8b-tetramethyl-2,3-dihydro-1h-cyclopenta[b][1]benzofuran

Research Excerpts

Overview

Aplysin is a brominated sesquiterpene with an isoprene skeleton and has biological activities.

ExcerptReferenceRelevance
"Aplysin is a brominated sesquiterpene with an isoprene skeleton and has biological activities. "( Aplysin Retards Pancreatic Necrosis and Inflammatory Responses in NOD Mice by Stabilizing Intestinal Barriers and Regulating Gut Microbial Composition.
Chang, Z; Cui, X; Gao, MQ; Jiang, Y; Liang, H; Liu, Y; Xu, H; Xue, M, 2020)		3.44

Actions

ExcerptReferenceRelevance
"Aplysin was found to enhance the tumor-suppressing capacity of TRAIL on several TRAIL-resistant cancer cell lines."( Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway.
Lin, X; Liu, G; Liu, J; Ma, L; Wu, N; Zheng, L, 2014)		2.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID402303Cytotoxicity against human Bel7402 cells by MTT assay2005Journal of natural products, Jun, Volume: 68, Issue:6
Sesquiterpenes from the red alga Laurencia tristicha.
AID402304Cytotoxicity against human HCT8 cells by MTT assay2005Journal of natural products, Jun, Volume: 68, Issue:6
Sesquiterpenes from the red alga Laurencia tristicha.
AID402305Cytotoxicity against human HeLa cells by MTT assay2005Journal of natural products, Jun, Volume: 68, Issue:6
Sesquiterpenes from the red alga Laurencia tristicha.
AID402302Cytotoxicity against human BGC823 cells by MTT assay2005Journal of natural products, Jun, Volume: 68, Issue:6
Sesquiterpenes from the red alga Laurencia tristicha.
AID402301Cytotoxicity against human A549 cells by MTT assay2005Journal of natural products, Jun, Volume: 68, Issue:6
Sesquiterpenes from the red alga Laurencia tristicha.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's8 (66.67)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.44 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.71 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
temozolomide
[no description available]		7.110imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.1710dialdehydebiomarker
sesquiterpenes
[no description available]		3.85100
laurinterol
laurinterol: an antimicrobial agent isolated from the marine alga Laurencia okamurai. laurinterol : A sesquiterpenoid isolated from Laurencia intermedia and Aplysia kurodai and has been found to exhibit antibacterial activity,		7.2510organobromine compound;
phenols;
sesquiterpenoid		antibacterial agent;
apoptosis inducer;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
metabolite
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.0810
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.110dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Atypical Mycobacterial Infection, Disseminated
[description not available]		02.2510
Innate Inflammatory Response
[description not available]		02.2510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.2510
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		07.2510
Acute Liver Injury, Drug-Induced
[description not available]		02.5720
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		02.5720
Disbacteriosis
[description not available]		02.1710
Alcohol Drinking
Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.		02.1710
Enteritis
Inflammation of any segment of the SMALL INTESTINE.		02.1710
Benign Neoplasms
[description not available]		02.1710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.1710
Alcoholic Liver Diseases
[description not available]		02.0810
Liver Diseases, Alcoholic
Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.		02.0810
Benign Neoplasms, Brain
[description not available]		02.5120
Glial Cell Tumors
[description not available]		02.5120
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.5120
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.5120